Why use the CV Health profile?
CV Health™ is a cardiovascular risk assessment that analyzes blood for lipid markers and independent risk factors leading to cardiovascular disease (CVD). Traditional lipid markers (such as LDL/HDL cholesterol and triglycerides) while informative, do not fully account for individual cardiovascular risk.
CV Health assesses a combination of standard lipid markers and advanced biomarkers that provide information on cholesterol metabolism, inflammation, and insulin resistance. With this information, clinicians can develop targeted treatments addressing specific metabolic areas to help minimize risk and support improved cardiovascular health.
Effective for Patients Experiencing:
CV Health can help clinicians identify individuals at risk for cardiovascular disease and allow for monitoring of previously abnormal results.
The CV Health Profile is appropriate for patients who:
- Have a family history of heart disease
- Are experiencing premature cardiovascular disease
- Have abnormal serum lipids
- Suffer from obesity and/or diabetes
- Are physically inactive
About the CV Health Profile
Using color-coded graphics, the CV Health report synthesizes test results into an easy-to-interpret format that clinicians can use to create targeted treatment programs aimed at lowering CVD risk. CV Health is an innovative test that features an advanced lipid profile that utilizes Nuclear Magnetic Resonance (NMR) fractionation technology, inflammatory markers, and a novel Insulin Resistance Score.
What are the CV Health profiles (CV Health or CV Health Plus Genomics)?
The CV Health Profiles are comprehensive evaluations of cardiovascular biomarkers featuring an advanced lipid profile that utilizes Nuclear Magnetic Resonance (NMR) fractionation technology, inflammatory biomarkers, and a novel Insulin Resistance Score.
Both CV Health profiles evaluate:
LDL, HDL, Total Cholesterol, Triglycerides
LDL-Particle Number and Size
HDL-Particle Number and Size
Independent Risk Factors
High Sensitivity CRP (hs-CRP)
Insulin Resistance Score by Lipid Fractionation, combining:
Small LDL-Particle Number
Large VLDL-Particle Number
Large HDL-Particle Number
In addition to the biomarkers listed above, CV Health Plus Genomics offers additional analyses for single nucleotide polymorphisms (SNPs) in four select genes related to cardiovascular health and blood coagulation:
APOE – plays a key role in lipid metabolism by removing dietary cholesterol (chylomicrons and VLDL) from the bloodstream
MTHFR – a key enzyme in folate metabolism, a required cofactor in the remethylation of homocysteine to methionine
Factor II (Prothrombin) – converts to active form, thrombin, forming the essential part of a blood clot Factor V (Leiden) – combines with Factor X to convert prothrombin to thrombin
When should a CV Health profile be considered?
The CV Health profiles address the clinical complexity of cardiovascular disease by providing a thorough assessment of cardiovascular health status for any individual, and particularly for those people with:
A family history of heart disease or stroke
Known cardiovascular disease and/or abnormal serum lipids
Associated risk factors including obesity, diabetes, poor dietary habits, sedentary lifestyle, and smoking
What advantages do the CV Health profiles offer compared to other diagnostics?
Traditionally assessed risk factors do not fully account for the development of cardiovascular disease, the number one cause of death in the US. The CV Health profiles offer a comprehensive evaluation featuring an advanced lipid profile that utilizes Nuclear Magnetic Resonance (NMR) fractionation technology, inflammatory markers, and a novel Insulin Resistance Score. These advanced biomarkers provide insight into metabolic areas associated with CVD risk, significantly increasing diagnostic yield. In addition, the genomics option provides insight into genetic predispositions that may increase risk for the development of cardiovascular disease.
What can clinicians and patients expect from CV Health profile testing?
In contrast to standard markers for cardiovascular disease risk, a structured comprehensive evaluation panel to evaluate fractionated biomarkers and independent risk factors provides clinical utility by supporting insight into development of personalized treatments. Targeted therapeutic interventions addressing specific metabolic areas can help minimize risk and support improved cardiovascular health.
CV Health, blood: MET13